By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) 

75 Sidney Street, 4th Floor

Cambridge  Massachusetts  02139  U.S.A.
Phone: 617-299-5000 Fax: 617-995-4995


Key Statistics

Ownership: Public

Web Site: AVEO Oncology
Symbol: AVEO


Merck & Co.  Cancer

Company News
Feds Slap AVEO Oncology (AVEO) with $4 Million Fine for Misleading Investors About Cancer Drug 3/30/2016 6:53:28 AM
AVEO Oncology (AVEO), CANBridge Life Sciences Strike $134 Million Deal for AV-203 3/21/2016 5:47:40 AM
AVEO Oncology (AVEO) Reports Full Year 2015 Financial Results And Provides Business Update 3/15/2016 10:46:50 AM
AVEO Oncology (AVEO) To Present At The 28th Annual ROTH Conference 3/9/2016 11:02:05 AM
EUSA Pharma And AVEO Oncology (AVEO) Announce Submission Of Marketing Authorization Application For Tivozanib In Advanced Renal Cell Carcinoma 3/1/2016 10:44:50 AM
AVEO Oncology (AVEO) Acceptance Of Registration Dossier For Tivozanib In RCC By The Ministry Of Health Of The Russian Federation 2/22/2016 2:24:01 PM
AVEO Oncology (AVEO) To Present At The 18th Annual BIO CEO & Investor Conference 2/2/2016 11:35:10 AM
AVEO Oncology (AVEO) To Present At Biotech Showcase 2016 1/6/2016 11:48:03 AM
AVEO Oncology (AVEO), EUSA Pharma Form $396.5 Million Exclusive Licensing Agreement for Tivozanib in Europe 12/21/2015 7:34:28 AM
AVEO Oncology (AVEO) Reports Third Quarter 2015 Financial Results And Provides Business Update 11/9/2015 11:46:17 AM